EDARBI Drug Profile, 2024: EDARBI (azilsartan kamedoxomil) drug patents, FDA exclusivity, litigation, drug prices

by DrugPatentWatch

EDARBI Drug Profile, 2024

This report focuses on EDARBI and covers the following critical aspects of this drug:

United States patentsExpired United States patentsDistrict Court patent litigationEuropean supplementary protection certificates (SPCs)Clinical trialsDrug pricesFinished product suppliersRaw active pharmaceutical ingredient (API) sourcesFREE UPDATE: Send your receipt to DrugPatentWatch within 30 days for a free updat

• Format: Paperback
• Language: English
• ISBN: B0CRZ544PC
• ISBN13: 9798875590641
• Release Date: January 2024
• Publisher: Independently Published
• Length: 44 Pages
• Weight: 0.28 lbs.
• Dimensions: 0.1" x 8.5" x 11.0"